Zurcher Kantonalbank Zurich Cantonalbank Boosts Position in Illumina, Inc. (NASDAQ:ILMN)

Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in shares of Illumina, Inc. (NASDAQ:ILMN) by 30.9% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 81,267 shares of the life sciences company’s stock after buying an additional 19,202 shares during the quarter. Zurcher Kantonalbank Zurich Cantonalbank owned 0.05% of Illumina worth $11,316,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. Brown Brothers Harriman & Co. increased its holdings in shares of Illumina by 460.9% during the 1st quarter. Brown Brothers Harriman & Co. now owns 129 shares of the life sciences company’s stock valued at $45,000 after purchasing an additional 106 shares in the last quarter. State of Wyoming purchased a new position in shares of Illumina during the 2nd quarter valued at approximately $32,000. Penserra Capital Management LLC purchased a new position in shares of Illumina during the 1st quarter valued at approximately $64,000. Annis Gardner Whiting Capital Advisors LLC purchased a new position in shares of Illumina during the 3rd quarter valued at approximately $30,000. Finally, VisionPoint Advisory Group LLC increased its holdings in shares of Illumina by 344.6% during the 3rd quarter. VisionPoint Advisory Group LLC now owns 249 shares of the life sciences company’s stock valued at $34,000 after purchasing an additional 193 shares in the last quarter. 89.42% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

ILMN has been the subject of several recent research reports. HSBC lowered shares of Illumina from a “buy” rating to a “hold” rating in a report on Tuesday, January 16th. Barclays lifted their target price on shares of Illumina from $85.00 to $100.00 and gave the company an “underweight” rating in a report on Wednesday, April 10th. Stephens reaffirmed an “overweight” rating and set a $170.00 target price on shares of Illumina in a report on Wednesday, April 10th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $253.00 target price on shares of Illumina in a report on Tuesday, April 9th. Finally, TD Cowen cut shares of Illumina from an “outperform” rating to a “market perform” rating and set a $144.00 price target on the stock. in a research note on Thursday, January 4th. Two equities research analysts have rated the stock with a sell rating, nine have given a hold rating and nine have assigned a buy rating to the company. Based on data from MarketBeat.com, Illumina has an average rating of “Hold” and an average price target of $167.70.

Insider Activity

In other news, CEO Jacob Thaysen purchased 7,330 shares of the stock in a transaction dated Thursday, February 22nd. The shares were purchased at an average price of $135.29 per share, with a total value of $991,675.70. Following the transaction, the chief executive officer now owns 14,861 shares in the company, valued at approximately $2,010,544.69. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Corporate insiders own 0.17% of the company’s stock.

Illumina Stock Performance

Shares of ILMN opened at $117.43 on Friday. Illumina, Inc. has a 52-week low of $89.00 and a 52-week high of $229.58. The company has a quick ratio of 1.29, a current ratio of 1.66 and a debt-to-equity ratio of 0.26. The firm’s fifty day moving average is $133.37 and its two-hundred day moving average is $127.94.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings results on Thursday, February 8th. The life sciences company reported $0.14 earnings per share for the quarter, beating the consensus estimate of $0.01 by $0.13. The firm had revenue of $1.12 billion for the quarter, compared to analysts’ expectations of $1.09 billion. Illumina had a negative net margin of 25.78% and a positive return on equity of 2.20%. The company’s revenue was up 3.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.14 EPS. Equities analysts predict that Illumina, Inc. will post 0.91 earnings per share for the current fiscal year.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.